Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
Фаза 3
Завершено
NCT05558410
| Заболевание | Acute Pain |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Vertex Pharmaceuticals Incorporated |
|---|
| Статус | Завершено |
|---|
| Участники | 1,118 участн. |
|---|
| Вмешательство | Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP) |
|---|
| Дата начала | 10.10.2022 |
|---|
| Дата завершения | 25.08.2023 |
|---|
| Публикация результатов | 1.07.2025 |
|---|
Кратко
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo
0 to 48 hours After First Dose of Study Drug · units on a scale
| Placebo | 70.1 ± 6.1 units on a scale |
|---|
| Suzetrigine (SUZ) | 118.4 ± 4.3 units on a scale |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.